Role and therapeutic potential of the NEDD4 family in breast cancer
Xiaoxiao Zhang, Sijie Li
TL;DR
This paper reviews how the NEDD4 family of proteins influences breast cancer and could lead to new treatments.
Contribution
The paper synthesizes current understanding of NEDD4 family interactions in breast cancer signaling pathways.
Findings
The NEDD4 family is aberrantly expressed in breast cancer progression.
NEDD4 interacts with tumor-related signaling pathways in breast cancer biology.
NEDD4 could serve as a novel prognostic marker or treatment target.
Abstract
The high incidence and mortality rates of breast cancer (BC) continue to pose a significant threat to patient survival and life expectancy. An increasing number of recent studies have demonstrated the crucial role of the ubiquitin-proteasome system (UPS) in cancer initiation and progression. Of particular significance is the aberrant expression of the NEDD4 family, which belongs to the HECT-type E3 ubiquitin ligases, in BC progression. This review synthesizes current knowledge about the interactions between the NEDD4 family and various tumor-related signaling pathways and their roles in BC biology, providing a theoretical foundation for exploring novel prognostic markers and treatment strategies.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsUbiquitin and proteasome pathways · Glycosylation and Glycoproteins Research · Peptidase Inhibition and Analysis